Cybin Inc Stock Price, News & Analysis

Cybin, a biopharmaceutical company focused on advancing "Psychedelics to Therapeutics™", will have its CEO Doug Drysdale participate in a fireside chat at the Aegis Virtual Conference on February 24, 2022, at 2:00 p.m. ET. The conference runs from February 23 to February 25, 2022. Interested viewers can access the event through a provided link, with an archived webcast available later on Cybin's investor relations site. Founded in 2019 and headquartered in Canada, Cybin aims to create safe therapeutics for mental health issues.

Cybin announced significant advancements in its clinical programs during Q3 2021, focusing on psychedelic therapies for mental health. The company is preparing for a Phase 1/2a trial of CYB003 targeting major depressive disorder and alcohol use disorder, following a supportive meeting with the UK MHRA. Financially, it reported C$63.6 million in cash, with a Q3 net loss of C$17.2 million. Cybin continues to build its intellectual property portfolio, including a recent U.S. patent for CYB004.

Cybin Inc. has received a crucial composition of matter patent for its investigational deuterated DMT compound, CYB004, from the U.S. Patent and Trademark Office. This patent, expiring in 2041, reinforces the company’s intellectual property in psychedelics and protects CYB004 as a new chemical entity. Preclinical studies show that CYB004 could alleviate negative experiences linked to classical DMT while boosting therapeutic effects. The company plans to submit a clinical trial application for a pilot study of CYB004 in mid-2022, with hopes for significant advancements in treating anxiety disorders.

Cybin Inc. has announced that its subsidiary, Adelia Therapeutics, has achieved key milestones as per a December 2020 contribution agreement. This entitles Adelia's shareholders to receive approximately $551,171.99 CAD (about $437,229.88 USD) in Class B shares, exchangeable into common shares of Cybin on a 10:1 basis. This exchange process will be phased, allowing 33.33% of shares to be exchanged by December 2022, 66.67% by December 2023, and 100% thereafter. Cybin is focused on developing psychedelic-based therapies to address mental health issues.

Cybin Inc. (AMEX:CYBN) will report its third-quarter financial results for the period ending December 31, 2021, on February 10, 2022. A conference call will take place at 8:30 a.m. (EST) on the same day, featuring CEO Doug Drysdale and the management team, who will discuss the results and answer questions. Cybin is focused on developing safe and effective therapeutics for mental health issues, leveraging partnerships with leading scientists and proprietary drug discovery platforms. Investors can access a webcast of the call.

Cybin announced approval from an Institutional Review Board for a feasibility study using Kernel's neuroimaging technology to assess ketamine's psychedelic effects on brain activity. This study, authorized by the FDA in October 2021, aims to provide quantitative data on brain activity related to psychedelics, enhancing understanding and potential treatment options for mental health disorders. Enrollment is expected to start in early 2022. Cybin will retain exclusive rights to innovations discovered through this study, aligning with its goal to advance psychedelics to therapeutics.

Cybin Inc. (NYSE AMERICAN:CYBN) has announced that its subsidiary, Adelia Therapeutics Inc., has achieved a milestone under a contribution agreement dated December 4, 2020. As a result, 15,611.4 Class B common shares will be issued to Adelia shareholders, fulfilling a payment obligation of approximately $235,528.90 (CAD). The effective issue price is about $15.09 per Class B Share, which can be exchanged for Cybin Shares at a ratio of 10:1. This strategic move indicates Cybin's commitment to advancing its psychedelic pharmaceutical therapies.

Cybin Inc. (NYSE American:CYBN) provided a year-end summary highlighting significant milestones achieved in 2021. The company expanded its workforce from 5 to over 55 employees globally and partnered with nearly 50 organizations, conducting over 90 preclinical studies. Major achievements included FDA approvals for clinical trials, promising data for CYB003 and CYB004, and a successful capital raise of $70M, totaling over $120M since inception. Cybin aims to initiate four first-in-human clinical studies in 2022, focusing on mental health treatments.

Cybin, a biopharmaceutical company focused on developing therapeutics from psychedelics, announces CEO Doug Drysdale's participation in two virtual investor conferences. The first is the 11th Annual LifeSci Partners Annual Corporate Access Event from January 5-7, 2022, where he will discuss psychedelics on January 5 at 10:00 a.m. ET. The second is the H.C. Wainwright Bioconnect Conference from January 10-13, 2022, featuring a fireside chat available on-demand starting January 10 at 7:00 a.m. ET. More details can be accessed through the company's investor relations website.